Add 3.0 mL bacteriostatic water to the 3 mL vial, aiming down the wall, then swirl gently until clear
The SELECT trial (N=17,604) added a cardiovascular dimension: semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with overweight or obesity and established cardiovascular disease, over a mean follow-up of 34.2 months [6]
No, semaglutide is formulated for once-weekly administration
Injectable peptides may be detectable longer than oral or topical forms due to different pharmacokinetic profiles
Repeated measures REML Mixed Models were used to reflect the design and properly compare preparation condition within each subject before amalgamating these comparisons across subjects
GLP-1RAs, glucagon-like peptide-1, receptor agonists